Posted: 20 February 2024
Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announces the appointment of Anne Anderson as independent non-executive director (NED) of Immutep Limited, effective from today.
Ms Anderson has extensive board and leadership experience serving Australian and international companies. She brings considerable capability across capital markets, risk management and governance to Immutep’s Board.
Anne currently serves as NED of leading Australian wealth manager, BTFM and was previously on the Board of an unlisted subsidiary of Ingenia Communities Group. She currently holds a portfolio of advisory and committee roles including as a Member of the Advisory Board to The Treasury (Australia), Member of the EnergyCo Transmission Acceleration Facility Investment Committee for the NSW Treasury, Advisor to the REST Board Investment Committee, Independent Member of the Minderoo Foundation and E&P Financial Group Investment Committees and Member of the ASIC Consultative Panel.
Prior to her NED and committee roles, she completed an executive career of more than 35 years spanning the energy and global financial services sectors. She held several Managing Director roles with UBS Asset Management, including leading its Asia Pacific Fixed Income business where she doubled assets under management from A$16 billion to A$28 billion, chaired various global investment committees and was a member of the global executive leadership team.
“Attracting a Board member of Anne’s high calibre is testament to Immutep’s robust strategic plans and strong leadership team. Her skills, experience and vast network will support the Company’s corporate objectives as we execute our larger trials for efti and pursue our commercialisation strategy. Aligned with Immutep’s values, Anne has a passion for bringing together the philanthropic, community and business sectors to solve some of the world’s biggest challenges. We are excited to benefit from this passion in the fight against cancer and autoimmune disease. It is with great pleasure that we welcome Anne to Immutep’s Board,” said Dr Russell Howard, Chairman of Immutep.
Based in Sydney, Australia, Anne holds a Bachelor of Economics, a Master of Applied Finance from Macquarie University and is a graduate of the Australian Institute of Company Directors.
